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Unveiling the gut microbiota 
composition and functionality 
associated with constipation 
through metagenomic analyses
Leonardo Mancabelli1, Christian Milani  1, Gabriele Andrea Lugli1, Francesca Turroni1, Marta 
Mangifesta1,2, Alice Viappiani2, Andrea Ticinesi  3, Antonio Nouvenne3, Tiziana Meschi3, 
Douwe van Sinderen4 & Marco Ventura1
Functional constipation (FC) is a gastrointestinal disorder with a high prevalence among the general 
population. The precise causes of FC are still unknown and are most likely multifactorial. Growing 
evidence indicates that alterations of gut microbiota composition contribute to constipation 
symptoms. Nevertheless, many discrepancies exist in literature and no clear link between FC and 
gut microbiota composition has as yet been identified. In this study, we performed 16 S rRNA-based 
microbial profiling analysis of 147 stool samples from 68 FC individuals and compared their microbial 
profiles with those of 79 healthy subjects (HS). Notably, the gut microbiota of FC individuals was shown 
to be depleted of members belonging to Bacteroides, Roseburia and Coprococcus 3. Furthermore, the 
metabolic capabilities of the gut microbiomes of five FC and five HS individuals were evaluated through 
shotgun metagenomics using a MiSeq platform, indicating that HS are enriched in pathways involved 
in carbohydrate, fatty acid and lipid metabolism as compared to FC. In contrast, the microbiomes 
corresponding to FC were shown to exhibit high abundance of genes involved in hydrogen production, 
methanogenesis and glycerol degradation. The identified differences in bacterial composition and 
metabolic capabilities may play an important role in development of FC symptoms.
The human gastrointestinal tract is colonized by complex communities of microorganisms, i.e. the gut micro-
biota, that are involved in several physiological functions of the host. These encompass metabolic, nutritional, 
physiological and immunological processes that are vital to maintain the host’s health status1, 2. In this context, 
alterations in the gut microbiota composition have been linked to certain common human intestinal diseases, 
such as pseudomembranous colitis (CDI)3–8, ulcerative colitis (UC)9–11 and Crohn’s disease (CD)9, 12, 13. However, 
changes in the gut microbiota composition are also considered to play a crucial role in the establishment of 
gut related disorders such as irritable bowel syndrome (IBS)14–16. Functional constipation (FC) is a common 
gastrointestinal disorder with a prevalence between 5% and 20% of the general population17, 18, provoking a sig-
nificant impact on quality of life19. In fact, it can result in discomforts such as abdominal distension, abdominal 
pain, headache, dizziness and loss of appetite20. Despite its high prevalence, only a small number of studies have 
investigated its possible correlation with particular gut microbiota alterations. Additionally, most of these studies 
relied on culture-based methods that are unable to assess the unculturable portion of the gut microbiota21, 22. 
Moreover, the functional implications of these alterations and their impact on host physiology have never been 
assessed. Recently, two metagenomic studies compared the microbial population of stools collected from con-
stipated and healthy individuals, highlighting an altered fecal microbiome associated with constipation23, 24. 
However, these studies were limited by the small sample size and heterogeneity of participants (including women 
or obese children). Furthermore, it is worth mentioning that the observed differences in microbiota composition 
among healthy and constipated patients suffer from a number of discrepancies20.
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Here, in order to identify a statistically significant and comprehensive correlation between microbiota and 
constipation, we performed 16 S rRNA-based profiling analysis of 147 stool samples collected from 68 functional 
constipated (FC) and 79 healthy subjects (HS). Furthermore, in order to better understand the role of the micro-
biome and its metabolic impact on the host, the gut microbiome of a random subsampling of 10 samples, five FC 
and five HS samples, was reconstructed and analyzed in detail by shotgun metagenomic analyses.
Results and Discussion
Patient enrollment and collection of fecal samples. In this study, we collected and analyzed 147 
human stool samples from Italian subjects. More specifically, we obtained 68 samples from individuals affected 
by functional constipation (FC), while 44 samples were collected from healthy subjects (HS). The HS dataset 
was supplemented with data from 35 samples that we published previously8, 25. Notably, these samples had been 
collected and processed using the same protocols as followed for the 112 samples sequenced in the current 
study (see below for details). Moreover, analysis of variance of beta-diversity was performed between each pool 
of samples processed in different sequencing runs, and the obtained data showed absence of any batch effects 
(Fig. S1a). In order to identify microbial biomarkers of functional constipation across all age ranges, we selected 
individuals with an age ranging from 4 to 94 (average age: 42 ± 22 years) (Table S1). Remarkably, beta-diversity 
and PERMANOVA analyses displayed absence of age-related clustering of the samples (Fig. S1b). Moreover, the 
enrolled individuals were not taking prebiotics and/or probiotics, not undergoing antibiotic treatment or any 
other medical therapy (including those specific for functional constipation such laxatives for one week prior 
sampling) and not suffering from acute or severe intestinal diseases such as ulcerative colitis (UC), Crohn’s dis-
ease, acute inflammatory bowel disease (IBD), intestinal cancer and enteritis. Notably, functionally constipated 
individuals also reporting symptoms typical of IBS-C, such as abdominal pain, were excluded from this study. The 
selected individuals affected by functional constipation fulfill the ROME-III criteria and manifested infrequent 
bowel movements that are defined as three or less defecations per week26. Notably, statistical assessment of diet 
homogeneity of FC and HS groups revealed absence of statistically significant differences (Table S2). In order to 
avoid discrepancies in the in silico data, all newly sequenced as well as previously published datasets included in 
this study were subjected to bioinformatic analysis using the same pipeline based on a custom script for the Qiime 
software suite and the same 16 S rRNA database (see Methods for details).
Intra- and Inter-individual variability among healthy and functionally constipated sub-
jects. Stool samples from the 147 individuals enrolled in this study were obtained in order to assess the micro-
biota composition based on 16 S rRNA-based sequencing analysis, as described previously27. MiSeq-mediated 
sequencing of the samples produced a total of 18,673,728 reads with an average of 127,032 ± 69,090 reads per 
sample (Table S2). Quality and chimera filtering produced a total of 10,164,847 filtered reads with an average of 
69,149 filtered reads per sample, and ranging from 185,347 to 10,440 reads (Table S2).
Evaluation of rarefaction curves obtained through the Shannon and Chao1 biodiversity indeces calculated 
for 10 sub-samplings of sequenced read pools showed that both curves tend to reach a plateau. Therefore, in all 
cases the retrieved sequencing data is considered adequate to cover the vast majority of biodiversity contained 
within the samples (Fig. 1). Interestingly, average rarefaction curves revealed a difference between FC and HS 
samples in that, on average, the former samples were shown to exhibit a higher level of gut microbiota complexity 
compared to the latter samples. Statistical analysis, calculated for the highest sub-sampling point reached by all 
samples, i.e. 30,000 reads, showed that the two curves significantly differ based on a one-way analysis of variance 
(ANOVA) (p-value < 0.05). The observed dissimilarity of the alpha-diversity between FC and HS is in accordance 
with a previous study24, being indicative of differences in bacterial composition and corresponding metabolic 
potential (see below). In order to evaluate the inter-individual differences between FC and HS samples in more 
detail, we assessed the beta-diversity28 by means of unweighted UniFrac29 and represented the results through a 
3-Dimensional Principal Coordinate Analysis (PCoA). The PCoA plot shows that the majority of the samples 
are grouped as two different clusters that correspond to FC or HS individuals, thus highlighting an intriguing 
difference in microbiota composition between individuals that suffer from functional constipation and healthy 
individuals (Fig. 1). Notably, the obtained results were statistically supported by PERMANOVA analyses (p-value 
of <0.001).
Taxonomic profiling of the gut microbiota of functionally constipated and healthy individu-
als. Inspection of the predicted taxonomic profiles showed that both FC and HS samples possess a prepon-
derant presence of the phyla Bacteroidetes (50.44% ± 18.29% and 58.37% ± 16.59%, respectively; p-value < 0.05) 
and Firmicutes (44.19% ± 17.02% and 36.65% ± 15.65%, respectively; p-value < 0.05), although with a signif-
icantly different average relative abundance (Fig. S2). When analyzed at genus level, the FC group displayed 
high levels of Bacteroides (34.25% ± 18.56%), Faecalibacterium (6.85% ± 6.19%), Alistipes (6.48% ± 9.69%), 
Lachnospira (4.44% ± 6.13%) and Unclassified member of Lachnospiraceae family (3.92% ± 2.40%). Similarly, 
the most represented taxa detected in HS samples were Bacteroides (45.23% ± 17.90%), Alistipes (5.34% ± 5.60%) 
and Unclassified member of Lachnospiraceae family (4.66% ± 4.38%).
Comparative analysis of the 331 bacterial taxa predicted by genus-level analysis revealed that 23 genera 
appeared to be present only in HS samples, while 17 were uniquely present in FC subjects (Table. S3). Analysis of 
the proportion of these unique genera found in each group, i.e. the prevalence, showed that these taxa are present 
in <20% of FC or HS profiles, thus indicating the absence of specific microbial biomarkers whose presence or 
absence is associated with constipation while pointing at a probable role played by the overall gut microbiota at 
functional level.
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Difference in gut microbiota composition. In order to evaluate possible differences in bacterial 
composition, ANOVA statistical analysis was employed to compare the average relative abundance in FC and 
HS groups of genera with an absolute percentage difference >0.1% (Fig. 2). Interestingly, the comparison 
between HS and FC datasets showed that profiles obtained from HS individuals are characterized by a statis-
tically significant over-representation of Bacteroides (% absolute 1.28%, p-value < 0.01), Roseburia (% abso-
lute 1.28%, p-value < 0.01) and Coprococcus 3 (% absolute 0.14%, p-value < 0.01) and a statistically significant 
Figure 1. Evaluation of the alpha- and beta-diversity in the 147 analyzed samples. Panel a reports the average 
rarefaction curves based on the Chao1 and Shannon index at increasing sequencing depth of FC and HS 
samples. Panel b shows the predicted PCoA through two three-dimensional images and two-dimensional 
sections. FC and HS datasets and corresponding clusters are colored in blue and red, respectively.
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under-representation of genera belonging to the Ruminococcaceae family such as Faecalibacterium (% abso-
lute −3.54%, p-value < 0.01) (Fig. 2). The depletion of the Bacteroides genus in FC samples may be correlated 
with alterations of the intestinal motility and secretory functions due to changes in the amount of available 
physiologically active substances in the metabolic environment of the gut20, 30. In fact, the higher abundance of 
butyrate-producing taxa, such as Coprococcus and Roseburia, observed in HS samples may explain a faster colonic 
transit due to the motility-stimulating effect exerted by butyrate in the gut1. In this context, previous studies have 
reported that butyrate-producing taxa may stimulate colonic motility by induction of serotonin release or by facil-
itating cholinergic pathways by means of butyrate production31, 32. In contrast, despite being a butyrate-producer, 
Faecalibacterium is significantly more abundant in FC samples. Interestingly, this genus has been reported to 
contribute to the pathogenesis of constipation via several mechanisms, such as inhibition of mucin secretion and 
reduction of stool volume24.
Metagenomic characterization of FC and HS microbiomes. A total of 10 individuals were selected 
among the two clusters obtained from the PCoA analysis (Fig. 1b) as representatives of the FC and HS groups, and 
total bacterial DNA extracted from corresponding fecal samples was subjected to Illumina shotgun sequencing. 
These samples were selected on the basis of their microbial profiles that were shown to be closer to the average for 
each group. Collected read pools ranged from 8,656,289 to 2,885,092 after quality filtering, with an average number 
of reads per sample of 6,130,802 (Table S4). These data were then utilized for the reconstruction of metabolic path-
way profiles in the analyzed microbiomes by means of a custom script based on the MetaCyc database33. A com-
parison between the averages of functionally constipated and the averages of healthy samples showed a significant 
difference in 629 pathways (p-value < 0.05). Of the latter, 327 and 302 pathways were more abundant in FC and HS 
samples, respectively (Table S5). Interestingly, the HS samples exhibited a higher abundance of genes (p-value < 0.05) 
involved in carbohydrate (increase of 21.15%) and fatty acid metabolism (increase of 25.93%) as compared to FC 
individuals (Fig. 3b). These pathways are implicated in production of short-chain fatty acids (SCFAs) and may play 
a role in stimulating ileal propulsive contractions through an enteric cholinergic reflex, thereby counteracting func-
tional constipation20, 34–36. Moreover, FC samples were shown to contain a higher abundance of genes involved in 
methanogenic pathways (increase of 24.96%, p-value < 0.01) and a predicted higher capability to produce hydrogen 
(increase of 113.69%, p-value 0.05) as compared to HS (Table S5, Fig. 3b). Thus, our data are consistent with previous 
observations and suggest that the (abundant) presence of methanogenic and H2-consuming populations influence 
colonic motility and visceral sensitivity, and generate chronic constipation along with several correlated symptoms, 
such as flatulence and abdominal distension37, 38. Interestingly, datasets obtained from functionally constipated indi-
viduals showed lower abundance of genes involved in methylglyoxal degradation as compared to healthy samples 
(decrease of −25.18%, p-value < 0.05) (Fig. 3b). Methylglyoxal is produced by intestinal bacteria and it is reported 
be a potential toxic metabolite that can be involved in many gut diseases, including functional constipation39. 
Furthermore, comparison between HS and FC samples highlights a significant difference in pathways implicated in 
Figure 2. Exploration of the diversity in HS and FC groups. The bar plot reports only genera with an absolute 
percentage difference between HS and FC averages >0.1% and a p-value < 0.05, evaluated by means of ANOVA 
statistical analysis. The table indicates the bacterial genera, the relative abundance and the prevalence of each 
group, the relative percentage difference and the p-value.
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glycerol degradation (decrease of −58.93% in HS, p-value < 0.05) (Fig. 3b). Glycerol is known to cause an osmotic 
effect in the rectum and for this reason is used to treat constipation40. Therefore, the increased ability to degrade glyc-
erol by FC samples may induce and promote the symptoms of constipation. Nevertheless, despite the fact that the 
use of laxatives in the week before sampling was considered as a exclusion criterion, this observation may be linked 
to previous and prolonged use of PEG or glycerol suppositories.
In addition, we evaluated co-variance between the bacterial genera and metabolic pathways displaying 
difference in abundance (ANOVA p-value < 0.05) in FC as compared to HS subjects. Force-driven network 
representation of these data revealed that Bacteroides (124 co-variances, p-value < 0.05), genera belonging 
Ruminococcaceae family (a total of 270 co-variances, p-value < 0.05) and the methanogenic genus Gelria (108 
interactions, p-value < 0.05) exert a key role in modulating the metabolic functionalities of the gut microbiome 
that are altered during FC (Fig. 4a).
Moreover, a force-driven network representation based on the above-discussed pathways that may be related 
to FC development revealed that the Firmicutes phylum positively correlates with pathways involved in hydro-
gen production and methanogenesis, while Bacteroides correlates positively with the methylglyoxal degradation 
pathways (Fig. 4b). These results reflect the putative beneficial role played by Bacteroides to counter FC as also 
suggested by the higher abundance of this genus in HS with respect to FC samples (see above). Notably, an in 
depth analysis of 16 S rRNA OTUs of HS samples revealed that 17.33% of the reads belonging to the Bacteroides 
genus correspond to unknown species, followed by Bacteroides vulgatus (13.83%), Bacteroides uniformis (4.21%) 
and Bacteroides fragilis (1.74%), thus indicating that further genomic analyses are still needed to shed light on the 
biological role of this genus in protecting against or in preventing FC.
Conclusions
Functional constipation is a widespread gastrointestinal disorder responsible for difficult or infrequent bowel 
movements defined as three or less defecations per week26. Despite the high worldwide prevalence of FC, a clear 
anatomical or physiological cause for this disorder has yet to be identified, thus pointing at a possible role exerted 
by the gut microbiota. Here, we confirm preliminary findings regarding gut microbiota compositional shifts in 
individuals affected by FC as compared to healthy controls, which are concurrent with a statistically significant 
increase of the gut microbiota biodiversity. Moreover, statistical analysis revealed alterations in relative abun-
dance of specific taxa, such as Bacteroides and Feacalibacterium. Disregarding the fact that the cause of such 
taxonomic changes can’t be linked to a specific physiological cause and may simply reflect altered transit time 
or diet, these taxa will be pivotal for diagnostic and prophylactic purposes as statistically-supported microbial 
biomarkers of constipation. Intriguingly, identification of taxa typically associated to a healthy gut status, e.g. the 
anti-inflammatory genus Feacalibacterium, as a biomarker of functional constipation, highlights that increased 
relative abundance of certain taxa in the presence of a gut disorder may not reflect a taxa-specific role in patho-
genesis but may be linked to a global alteration of gut microbiota’s homeostasis. Notably, the taxonomic profiles 
retrieved from faecal samples include both the autochthonous as well as the allochthonous microbiota, and may 
thus not be fully representative of the resident gut microbial population. In contrast, the use of biopsies from 
mucosal samples would be ideal to provide information on the indigenous microbiota41. Nevertheless, collection 
of fecal samples is less invasive and does not require specific clinical procedures. Thus, for a rapid screening aimed 
at the identification of biomarkers associated with specific disorders, e.g. functional constipation, the use of stool 
samples does not suffer from the aforementioned problems associated with collection of biopsies.
While exploration of the functional role of the gut microbiota in fecal transit time42 has been attempted in 
the past through analysis of urine metabolites, the whole gut microbiome metabolic potential and its impact on 
host physiology and development of functional constipation has yet to be elucidated. To overcome this gap, we 
profiled metabolic pathways of microbiomes corresponding to functionally constipated and healthy individuals. 
Figure 3. Functional characterization of FC and HS microbiomes. The bar plot shows the relative difference 
between the average abundance in HS and FC subjects of each pathway displaying ANOVA with p-value < 0.05.
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Figure 4. Co-variance network of bacterial genera and metabolic pathways with statistically significant 
difference in abundance between FC and HS subjects. Panel a shows a force-driven network based on 
the predicted co-variances with p-values < 0.05 between the genera and metabolic pathways identified as 
statistically altered in FC as compared to HS. Panel b reports a force-driven network based on the predicted co-
variances with p-values < 0.05 between genera and metabolic pathways putatively involved in FC development. 
Co-variances with p-values < 0.05 are used to define the attractive or repulsive force of the edges. The node size 
is proportional to the number of co-variances. Node color indicates phylum or pathway category as reported in 
the image. The taxonomy, i.e. bacterial genera, of the nodes is indicated with number, as listed in the table.
www.nature.com/scientificreports/
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The here reconstructed gut microbiome of individuals affected by functional constipation revealed for the first 
time that the FC microbiome is characterized by a high abundance of genes involved in hydrogen production, 
methanogenesis and glycerol degradation. In contrast, the microbiomes of HS samples showed an increase of 
pathways implicated in carbohydrate and fatty acid metabolism, and in methylglyoxal degradation. Alteration of 
these metabolic pathways appears to impact on functional constipation and related symptoms, thus highlighting 
the key functional role exerted by the gut microbiome in maintaining the health status of the host. Nevertheless, 
due to the limited number of samples that were analysed by shotgun sequencing, additional experiments are 
needed to validate these observations.
Altogether, taxonomic and functional data reported in this study represent a solid base for future development 
of both prophylactic screenings and therapies for functional constipation based on alterations of gut microbiota 
composition through personalized diet or pre- and pro-biotic treatments.
Methods
Datasets included in this study. We enrolled 68 volunteers suffering from functional constipation (FC) 
and 44 healthy subjects (HS) in an outpatient clinic setting. The individuals affected by functional constipation 
presented infrequent bowel movements and fulfilled the ROME-III criteria. A stool sample, consisting of 6–10 g 
fresh fecal material, was obtained from each subject and immediately frozen at −80 °C until it was processed for 
DNA extraction. DNA was extracted from each stool sample using the QIAamp DNA Stool Mini kit (Qiagen Ltd, 
Strasse, Germany) following the manufacturer’s instructions (Qiagen Ltd). The study protocol was approved by 
the Ethics Committee of the University of Parma. Informed consent was obtained from all participants. All inves-
tigations were carried out following the principles of the Declaration of Helsinki.
16 S rRNA gene amplification. Partial 16 S rRNA gene sequences were amplified from extracted DNA 
using primer pair Probio_Uni and/Probio_Rev, which targets the V3 region of the 16 S rRNA gene sequence27. 
Illumina adapter overhang nucleotide sequences were then added to the partial 16 S rRNA gene-specific ampli-
cons, which in turn were further processed by employing the 16 S Metagenomic Sequencing Library Preparation 
Protocol (Part no. 15044223 Rev. B—Illumina; see also below). Amplifications were carried out using a Verity 
Thermocycler (Applied Biosystems). The integrity of the PCR amplicons was analyzed by electrophoresis on a 
2200 TapeStation Instrument (Agilent Technologies, USA).
MiSeq sequencing of 16 S rRNA gene-based amplicons. PCR products obtained following amplifica-
tion of part of the 16 S rRNA gene sequences were purified by a magnetic purification step involving Agencourt 
AMPure XP DNA purification beads (Beckman Coulter Genomics GmbH, Bernried, Germany) in order to 
remove primer dimers. The DNA concentration of the amplified sequence library was estimated through fluori-
metric Qubit quantification system (Life Technologies). Amplicons were diluted to 4 nM and 5 μl of each diluted 
DNA amplicon sample was mixed to prepare the pooled final library. Sequencing was performed using an 
Illumina MiSeq sequencer with MiSeq Reagent Kit v3 chemicals.
Analysis of 16 S rRNA microbial profiling datasets. The fastq files were processed using QIIME28 as 
previously described27. Paired-end reads were merged, and quality control implementation allowed the reten-
tion of sequences with a length between 140 and 400 bp, mean sequence quality score >25 and with truncation 
of a sequence at the first base if a low quality within a rolling 10-bp window was found. Sequences with mis-
matched forward and/or reverse primers were omitted. 16 S rRNA operational taxonomic units (OTUs) were 
defined at ≥ 97% sequence homology using uclust43. All reads were classified to the lowest possible taxonomic 
rank using QIIME28 and a reference dataset from the SILVA database v. 12344. The microbial richness of the sam-
ples (alpha-diversity) was evaluated with the Chao1 and Shannon index through the alpha_rarefaction.py script 
included in the Qiime software suite using default parameters. Similarities between samples (beta-diversity) were 
calculated by unweighted uniFrac45. Principal coordinate analysis (PCoA) representations of beta-diversity were 
performed using QIIME28.
Shotgun metagenomics. DNA library preparation was performed using the Nextera XT DNA sample 
preparation kit (Illumina, San Diego, CA) according to the manufacturer’s instructions. In brief, 1 ng input DNA 
from each sample was used for library preparation. The isolated DNA underwent fragmentation, adapter ligation 
and amplification. The ready-to-go libraries were pooled equimolarly, denaturated and diluted to a sequencing 
concentration of 1.8 pM. Sequencing was performed on NextSeq. 550 instrument (Illumina, San Diego, CA), 
according to the manufacturer’s instructions, using the 2 × 150 bp High Output sequencing kit, and spike-in of 
1% PhiX control library.
Analysis of metagenomic datasets. The generated paired fastq files were filtered for reads with a quality 
score of <25, for sequences of human DNA, as well as for reads <80 bp. Bases were also removed from the end 
of the reads unless the average quality score in a window of 5 bp was >25. Reconstruction of bacterial metabolic 
pathways was performed using custom scripts based on htseq-count46 and the MetaCyc database33, respectively.
Statistical analyses. QIIME and SPSS software (www.ibm.com/software/it/analytics/spss/) were used to 
complete statistical analysis. All data were presented as means ± SEM. PERMANOVA were performed using 999 
permutations to estimate p-values for differences among populations. Furthermore, differential abundance of 
bacteria taxa and metabolic pathways were tested by one-way analysis of variance (ANOVA).
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Data Deposition. The 16 S rRNA profiling data sequenced in this study were deposited in the Sequence Read 
Archive (SRA) database under the SRP106879 accession number. Shotgun metagenomics data are accessible 
through SRA study accession number SRP106935.
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